Arvind K. Sood | Amgen, Inc. |
Robert A. Bradway | Amgen, Inc. |
David W. Meline | Amgen, Inc. |
Anthony C. Hooper | Amgen, Inc. |
Sean E. Harper | Amgen, Inc. |
David M. Reese | Amgen, Inc. |
Ying Huang | Bank of America Merrill Lynch |
Michael J. Yee | Jefferies LLC |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Christopher J. Raymond | Piper Jaffray & Co. |
Umer Raffat | Evercore ISI |
Terence Flynn | Goldman Sachs & Co. LLC |
Geoffrey C. Porges | Leerink Partners LLC |
Geoff Meacham | Barclays Capital, Inc. |
Cory W. Kasimov | JPMorgan Securities LLC |
Kennen MacKay | RBC Capital Markets LLC |
Phil Nadeau | Cowen & Co. LLC |
Carter Gould | UBS Securities LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Jim Birchenough | Wells Fargo Securities LLC |
Salim Syed | Mizuho Securities USA LLC |
Brian P. Skorney | Robert W. Baird & Co., Inc. |
My name is Ian and I will be your conference facilitator today for Amgen's Second Quarter 2018 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate we would like to request that you limit yourself to asking one question during the Q&A session. I would now like to introduce Arvind Sood, Vice President of Investor Relations.